NASDAQ:VRNA Verona Pharma (VRNA) Stock Forecast, Price & News $15.32 -0.04 (-0.26%) (As of 01:10 PM ET) Add Compare Share Share Today's Range$15.11▼$15.4350-Day Range$15.36▼$22.0952-Week Range$9.26▼$26.44Volume56,288 shsAverage Volume459,345 shsMarket Capitalization$9.74 billionP/E RatioN/ADividend YieldN/APrice Target$32.60 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Verona Pharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside112.8% Upside$32.60 Price TargetShort InterestBearish0.69% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.83Based on 3 Articles This WeekInsider TradingSelling Shares$1.46 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.86) to ($1.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.73 out of 5 starsMedical Sector842nd out of 966 stocksPharmaceutical Preparations Industry394th out of 444 stocks 3.5 Analyst's Opinion Consensus RatingVerona Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.60, Verona Pharma has a forecasted upside of 112.8% from its current price of $15.32.Amount of Analyst CoverageVerona Pharma has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted0.69% of the outstanding shares of Verona Pharma have been sold short.Short Interest Ratio / Days to CoverVerona Pharma has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.Change versus previous monthShort interest in Verona Pharma has recently increased by 14.25%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVerona Pharma does not currently pay a dividend.Dividend GrowthVerona Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VRNA. Previous Next 3.2 News and Social Media Coverage News SentimentVerona Pharma has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Verona Pharma this week, compared to 2 articles on an average week.Search Interest7 people have searched for VRNA on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Verona Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verona Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,460,799.00 in company stock.Percentage Held by InsidersOnly 3.90% of the stock of Verona Pharma is held by insiders.Percentage Held by InstitutionsOnly 9.89% of the stock of Verona Pharma is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Verona Pharma are expected to decrease in the coming year, from ($0.86) to ($1.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verona Pharma is -20.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verona Pharma is -20.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerona Pharma has a P/B Ratio of 5.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Verona Pharma (NASDAQ:VRNA) StockVerona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.Read More VRNA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VRNA Stock News HeadlinesOctober 3, 2023 | finance.yahoo.comVerona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023October 1, 2023 | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Shares Gap Down to $16.94October 4, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 29, 2023 | americanbankingnews.comAnalysts Set Verona Pharma plc (NASDAQ:VRNA) Target Price at $32.60September 26, 2023 | finance.yahoo.comRaleigh pharma preps for hiring spree, expands office footprint with subleaseSeptember 11, 2023 | msn.comVerona Pharma’s ensifentrine inches closer to approval decision in COPDSeptember 11, 2023 | markets.businessinsider.comVerona Pharma (VRNA) Receives a Buy from H.C. WainwrightSeptember 11, 2023 | finance.yahoo.comVerona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPDOctober 4, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 6, 2023 | finance.yahoo.comVerona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023August 31, 2023 | finance.yahoo.comChristina Ackermann Joins Verona Pharma as Non-Executive DirectorAugust 8, 2023 | seekingalpha.comVerona Pharma: Targeting The Large COPD MarketAugust 8, 2023 | finance.yahoo.comVerona Pharma plc (NASDAQ:VRNA) Q2 2023 Earnings Call TranscriptAugust 8, 2023 | finance.yahoo.comVerona Pharma plc's (NASDAQ:VRNA) institutional investors lost 14% over the past week but have profited from longer-term gainsAugust 6, 2023 | markets.businessinsider.comTruist Financial Sticks to Their Buy Rating for Verona Pharma (VRNA)August 3, 2023 | finance.yahoo.comVerona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateJune 30, 2023 | fool.comVerona Pharma Plc (NASDAQ: VRNA)June 28, 2023 | finance.yahoo.comVerona Pharma Announces Publication of Phase 3 ENHANCE Data in the American Journal of Respiratory and Critical Care MedicineJune 27, 2023 | markets.businessinsider.comWedbush Remains a Buy on Verona Pharma (VRNA)June 27, 2023 | markets.businessinsider.comTruist Financial Keeps Their Buy Rating on Verona Pharma (VRNA)June 27, 2023 | finanznachrichten.deVerona Pharma plc: Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPDJune 27, 2023 | finance.yahoo.comVerona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPDJune 16, 2023 | finance.yahoo.comVRNA - Verona Pharma plcJune 7, 2023 | msn.comTruist Securities Maintains Verona Pharma Plc - ADR (VRNA) Buy RecommendationJune 2, 2023 | markets.businessinsider.comVerona Pharma (VRNA) Gets a Buy from H.C. WainwrightMay 28, 2023 | msn.comVerona Pharma: Poised For A Breakthrough In COPD Treatment Amidst Favorable Financial PositionMay 18, 2023 | seekingalpha.comVerona Pharma: Revolutionizing COPD With First Triple Mechanism Inhaled DrugSee More Headlines Receive VRNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address VRNA Company Calendar Last Earnings8/03/2023Today10/04/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VRNA CUSIPN/A CIK1657312 Webwww.veronapharma.com Phone011-44-0-2032834200FaxN/AEmployees35Year FoundedN/APrice Target and Rating Average Stock Price Forecast$32.60 High Stock Price Forecast$35.00 Low Stock Price Forecast$31.00 Forecasted Upside/Downside+112.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-68,700,000.00 Net MarginsN/A Pretax Margin-11,151.31% Return on Equity-20.30% Return on Assets-17.79% Debt Debt-to-Equity Ratio0.07 Current Ratio26.29 Quick Ratio26.29 Sales & Book Value Annual Sales$460,000.00 Price / Sales21,225.85 Cash FlowN/A Price / Cash FlowN/A Book Value$3.05 per share Price / Book5.04Miscellaneous Outstanding Shares635,670,000Free Float610,879,000Market Cap$9.76 billion OptionableNot Optionable Beta0.27 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. David S. Zaccardelli (Age 58)Pres, CEO & Exec. Director Comp: $1.05MMr. Mark W. Hahn (Age 60)Chief Financial Officer Comp: $784.38kDr. Kathleen A. Rickard (Age 65)Chief Medical Officer Comp: $655kMs. Claire Louise Poll L.C.S.W. (Age 56)B.A., B Juris, LLB, ASIA, Gen. Counsel Ms. Victoria StewartDirector of CommunicationsMr. Matthew CasbonVP of Sales, Marketing & TrainingMs. Ostra JewellSr. VP of HRDr. Peter Spargo (Age 61)Sr. VP of Chemistry Manufacturing & Controls Dr. Tara Rheault M.P.H. (Age 46)Ph.D., Sr. VP of R&D Mr. Christopher MartinSr. VP of CommercialMore ExecutivesKey CompetitorsUnited TherapeuticsNASDAQ:UTHRSarepta TherapeuticsNASDAQ:SRPTLegend BiotechNASDAQ:LEGNTeva Pharmaceutical IndustriesNYSE:TEVADr. Reddy's LaboratoriesNYSE:RDYView All CompetitorsInsiders & InstitutionsAffinity Asset Advisors LLCSold 5,154 shares on 8/21/2023Ownership: 0.070%Legato Capital Management LLCBought 19,297 shares on 8/18/2023Ownership: 0.003%HighVista Strategies LLCSold 13,696 shares on 8/15/2023Ownership: 0.005%Goldman Sachs Group Inc.Bought 1,521 shares on 8/15/2023Ownership: 0.003%Wells Fargo & Company MNBought 12,400 shares on 8/15/2023Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions VRNA Stock - Frequently Asked Questions Should I buy or sell Verona Pharma stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VRNA shares. View VRNA analyst ratings or view top-rated stocks. What is Verona Pharma's stock price forecast for 2023? 5 brokerages have issued 12 month target prices for Verona Pharma's stock. Their VRNA share price forecasts range from $31.00 to $35.00. On average, they predict the company's share price to reach $32.60 in the next year. This suggests a possible upside of 112.2% from the stock's current price. View analysts price targets for VRNA or view top-rated stocks among Wall Street analysts. How have VRNA shares performed in 2023? Verona Pharma's stock was trading at $26.13 on January 1st, 2023. Since then, VRNA stock has decreased by 41.2% and is now trading at $15.36. View the best growth stocks for 2023 here. When is Verona Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our VRNA earnings forecast. How were Verona Pharma's earnings last quarter? Verona Pharma plc (NASDAQ:VRNA) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.16. What ETF holds Verona Pharma's stock ? ALPS Medical Breakthroughs ETF holds 60,171 shares of VRNA stock, representing 1.19% of its portfolio. What other stocks do shareholders of Verona Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Trevena (TRVN), Pfizer (PFE), Citius Pharmaceuticals (CTXR), electroCore (ECOR), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV) and Vaxart (VXRT). When did Verona Pharma IPO? (VRNA) raised $61 million in an initial public offering (IPO) on Thursday, April 27th 2017. The company issued 4,500,000 shares at a price of $13.49 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers. What is Verona Pharma's stock symbol? Verona Pharma trades on the NASDAQ under the ticker symbol "VRNA." How do I buy shares of Verona Pharma? Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Verona Pharma's stock price today? One share of VRNA stock can currently be purchased for approximately $15.36. How much money does Verona Pharma make? Verona Pharma (NASDAQ:VRNA) has a market capitalization of $9.76 billion and generates $460,000.00 in revenue each year. The company earns $-68,700,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. How can I contact Verona Pharma? Verona Pharma's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The official website for the company is www.veronapharma.com. The company can be reached via phone at 011-44-0-2032834200 or via email at verona@argotpartners.com. This page (NASDAQ:VRNA) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.